Caplin Point Laboratories LimitedNSE: CAPLIPOINT

Press Release May 12 2023

· Issued by Caplin Point Laboratories Limited

Filed with NSE ·

Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated May 12, 2023, titled "Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ketorolac Tromethamine Injection USP.".

View Attachment

6ix hasn’t read this filing yet.

Caplin Point Laboratories Limited on 6ix

Earlier from Caplin Point Laboratories

Later from Caplin Point Laboratories

All Caplin Point Laboratories news releases